Genmab and Immatics develop next-gen bispecific immunotherapies for cancer
Genmab AS and Immatics Biotechnologies GMBH penned a deal to discover and develop next-generative bispecific immunotherapies for cancer.
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.